» Articles » PMID: 32335561

Update on Treatment of COVID-19: Ongoing Studies Between Promising and Disappointing Results

Overview
Journal Infez Med
Date 2020 Apr 27
PMID 32335561
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

The COVID-19 pandemic represents the greatest global public health crisis since the pandemic influenza outbreak of 1918. We are facing a new virus, so several antiviral agents previously used to treat other coronavirus infections such as SARS and MERS are being considered as the first potential candidates to treat COVID-19. Thus, several agents have been used by the beginning of the current outbreak in China first and all over the word successively, as reported in several different guidelines and therapeutic recommendations. At the same time, a great number of clinical trials have been launched to investigate the potential efficacy therapies for COVID-19 highlighting the urgent need to get as quickly as possible high-quality evidence. Through PubMed, we explored the relevant articles published on treatment of COVID-19 and on trials ongoing up to April 15, 2020.

Citing Articles

Exploring the Therapeutic Potential of L. Phytochemicals: A Computational Study on Inhibiting SARS-CoV-2's Main Protease (Mpro).

Ali M, Sheikh H, Yaseen M, Faruqe M, Ullah I, Kumar N Molecules. 2024; 29(11).

PMID: 38893400 PMC: 11173994. DOI: 10.3390/molecules29112524.


Does COVID-19 impair V̇o in patients with cardiorespiratory disease? Insight from cardiopulmonary responses to maximal exercise pre- and post-illness.

Fernandes I, Balavenkataraman A, Bonvie-Hill N, Patel N, Taylor B, Helgeson S J Appl Physiol (1985). 2023; 135(5):1146-1156.

PMID: 37855032 PMC: 10979800. DOI: 10.1152/japplphysiol.00357.2023.


Risk Factors for Severity and Mortality in Adult Patients Confirmed with COVID-19 in Sierra Leone: A Retrospective Study.

Tu B, Lakoh S, Xu B, Lado M, Cole R, Chu F Infect Dis Immun. 2023; 2(2):83-92.

PMID: 37521952 PMC: 9112504. DOI: 10.1097/ID9.0000000000000037.


Histopathology of COVID-19: An illustration of the findings from fatal cases.

Rivera J, Corchuelo S, Naizaque J, Parra E, Meek E, Alvarez-Diaz D Biomedica. 2023; 43(1):8-21.

PMID: 37167459 PMC: 10481905. DOI: 10.7705/biomedica.6737.


Longitudinal profiles of plasma gelsolin, cytokines and antibody expression predict COVID-19 severity and hospitalization outcomes.

Asare-Werehene M, McGuinty M, Vranjkovic A, Galipeau Y, Cowan J, Cameron B Front Immunol. 2022; 13:1011084.

PMID: 36148234 PMC: 9489255. DOI: 10.3389/fimmu.2022.1011084.